GenSight Biologics is a clinical-stage biotechnology company discovering and developing novel therapies for mitochondrial and neurodegenerative diseases of the eye and central nervous system. To address these therapeutic areas, the Company leverages its integrated development platform by combining a gene therapy-based approach with its core technology platforms of mitochondrial targeting sequence and optogenetics.
GenSight's initial focus has been on developing therapies for severe retinal diseases, with the goal of preserving or restoring vision in patients suffering from sight-threatening ophthalmic diseases.
|Employees (est.) (Feb 2019)||37|
|Share Price (Oct 2017)||€5.2|
Market capitalization (31-Oct-2017)
Closing stock price (31-Oct-2017)
When was GenSight Biologics founded?
GenSight Biologics was founded in 2011.
Who are GenSight Biologics key executives?
GenSight Biologics's key executives are Bernard Gilly, Thomas Gidoin and Barrett Katz.
How many employees does GenSight Biologics have?
GenSight Biologics has 37 employees.
Who are GenSight Biologics competitors?
Competitors of GenSight Biologics include Touchlight Genetics, Blueprint Genetics and Osiris Therapeutics.
Where is GenSight Biologics headquarters?
GenSight Biologics headquarters is located at 74 Rue du Faubourg Saint-Antoine, Paris.
Where are GenSight Biologics offices?
GenSight Biologics has offices in Paris and New York.
How many offices does GenSight Biologics have?
GenSight Biologics has 2 offices.
Receive alerts for 300+ data fields across thousands of companies